[{"uuid": "d00b6aa5-6c98-3425-81ee-46769fd05d5c", "title": "Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/arcturus-therapeutics-present-guggenheim-securities-210100312.html", "providerPublishTime": 1738270860, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/vLtQadwJwr5d51qZYGiFbQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/a1ddad4021d1d55c0a5ce1e324cefba2", "width": 3600, "height": 1320, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/VK63.2pYs2g8LoKz.0tKBg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a1ddad4021d1d55c0a5ce1e324cefba2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT"]}, {"uuid": "76ca761a-28ac-3fa8-98ed-80c974885721", "title": "Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE\u00ae, a Self-amplifying mRNA Vaccine Against COVID-19", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/meiji-seika-pharma-receives-approval-080000736.html", "providerPublishTime": 1738310400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Lmw4XMqdfmbogM5s_WR68Q--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/781c2e51f45f417642d8c9c3fd720b42", "width": 3600, "height": 1320, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/g.oU1XMxoLB_qvNQYc.yhw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/781c2e51f45f417642d8c9c3fd720b42", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT"]}, {"uuid": "394a187f-f3d3-3401-8466-273a99bd8bcc", "title": "BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/btig-initiates-arcturus-therapeutics-holdings-120830936.html", "providerPublishTime": 1738066110, "type": "STORY", "relatedTickers": ["ARCT"]}, {"uuid": "218a83de-9cd2-3905-abd2-e10de7eb9269", "title": "Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine", "publisher": "Barrons.com", "link": "https://finance.yahoo.com/m/218a83de-9cd2-3905-abd2-e10de7eb9269/moderna-is-getting-%24590.html", "providerPublishTime": 1737487620, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_kc6REYMS1JrAuV5bYtjfA--~B/aD02NTt3PTMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e", "width": 320, "height": 65, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5waH37HKuL3X52B3V2GWrw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MRNA"]}, {"uuid": "70b2ecc4-aab5-3bec-9612-d2776dcaca38", "title": "As avian influenza A(H5N1) concerns continue, mRNA vaccines offer great potential", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/70b2ecc4-aab5-3bec-9612-d2776dcaca38/as-avian-influenza-a%28h5n1%29.html", "providerPublishTime": 1736865747, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/QPm6fi15KeAlyv2jRvyIlg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/a8900acd9721e11b7a6dba2fec6e01a5", "width": 1000, "height": 667, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zr3O71ZiiBcL5KD6xbA6_w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/a8900acd9721e11b7a6dba2fec6e01a5", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "283edafe-8439-32a3-9c09-b980405f95c6", "title": "Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-phase-130000469.html", "providerPublishTime": 1736514000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/hIocYN8Ctsvr.mo.8zUGRw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/ac54e348cbdbb282ae64749c55c47cc4", "width": 3600, "height": 1320, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/C13LWD3aqPHTpJwWa2JmeA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ac54e348cbdbb282ae64749c55c47cc4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT"]}, {"uuid": "73b65936-cb90-3138-b27f-21310a44e59d", "title": "Arcturus Therapeutics launches Phase I Avian Influenza trials in US", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/73b65936-cb90-3138-b27f-21310a44e59d/arcturus-therapeutics.html", "providerPublishTime": 1736525653, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ZcBwyIetAyYXRh3t.3rcHw--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/81b14bd2fbeb4c699ceb80cbaaec727e", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/AR0kTuojxiEkS6rFKHehcA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/81b14bd2fbeb4c699ceb80cbaaec727e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT", "GLDAF"]}, {"uuid": "833879d0-fac1-314c-ab58-a6c1ad65e66d", "title": "Arcturus Starts Dosing in Phase 2 Cystic Fibrosis, Ornithine Transcarbamylase Deficiency Treatment Studies", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arcturus-starts-dosing-phase-2-212612141.html", "providerPublishTime": 1736198772, "type": "STORY", "relatedTickers": ["ARCT"]}, {"uuid": "b3d5add3-93f2-316e-baa0-93980590b14c", "title": "Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-dosing-210100304.html", "providerPublishTime": 1736197260, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Cy_r84IvftmoFUjb6lEytQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/a1458068a3dc75394eb900ea7f8cfb8a", "width": 3600, "height": 1320, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/sYlWI8dvYGAyBEgHwJSYJQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a1458068a3dc75394eb900ea7f8cfb8a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT"]}, {"uuid": "ea5f8b0f-76cb-3016-a73f-d5f79ea294c7", "title": "Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu Fears Reignite Immunization Demand", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/vaccine-stocks-surge-moderna-jumps-162633280.html", "providerPublishTime": 1736267193, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/rMnuWSu.tAGhdu1m75xtzw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/c4618e69192265b5b79b95e66c15fe9f", "width": 400, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SwyXxXFL5RappmnNOJ2a.g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/c4618e69192265b5b79b95e66c15fe9f", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MRNA", "NVAX", "PFE"]}, {"uuid": "6766f4f5-9b20-369b-93ba-9bed1548ab6f", "title": "Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-arcturus-therapeutics-arct-worst-165508619.html", "providerPublishTime": 1733936108, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/jdpxesy9BmQakx8IrjNd7g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT"]}, {"uuid": "6cdd2e13-6ad9-3757-9e50-aed85f0e79d5", "title": "Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/arcturus-therapeutics-arct-reports-q3-225508197.html", "providerPublishTime": 1731020108, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n4.AbgyuCxTPgpWcYEizKw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARCT"]}]